DMRT2

Across TCGA pan-cancer cohorts, DMRT2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of DMRT2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where DMRT2 RNA is repressed in tumor relative to normal tissue. In most cancer types DMRT2 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and BLCA are the cancer types where DMRT2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DMRT2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	−4.618	<.001	12	view →
KIRP	Female	All	−4.569	<.001	11	view →
BLCA	All	All	+1.315	<.001	8	view →
BRCA	All	II,III,IV	−1.471	<.001	6	view →
LUAD	Male	All	−0.600	<.001	6	view →
LUSC	Female	All	+1.949	<.001	5	view →
KICH	All	II,III,IV	+1.868	.001	4	view →
PRAD	All	All	−0.554	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

DMRT2–KIRC

Open the KIRC breakdown →